Department of Genetics, Maria Sklodowska-Curie Institute - Oncology Centre, Warsaw, Poland.
Department of Gastroenterology and Hepatology, Medical Center for Postgraduate Education, Warsaw, Poland.
J Crohns Colitis. 2019 Apr 26;13(5):626-633. doi: 10.1093/ecco-jcc/jjy205.
The study investigates the practical utility of whole-blood gene expression profiling to diagnose inflammatory bowel diseases [IBDs].
The discovery cohorts included 102 and 51 paediatric IBD patients and controls, and 95 and 46 adult IBD patients and controls, respectively. The replication cohorts included 447 and 76 paediatric IBD patients and controls, and 271 and 108 adult IBD patients and controls, respectively. In the discovery phase, RNA samples extracted from whole peripheral blood were analysed using RNA-Seq, and the predictive values of selected biomarkers were validated using quantitative polymerase chain reaction [qPCR].
In all, 15 differentially expressed transcripts [adjusted p ≤0.05] were selected from the discovery sequencing datasets. The receiver operating characteristic curves and area under the curve [ROC-AUC] in replication analyses showed high discriminative power [AUC range, 0.91-0.98] for 11 mRNAs in paediatric patients with active IBD. By contrast, the AUC-ROC values ranged from 0.63 to 0.75 in comparison among inactive paediatric IBDs and active/inactive adult IBDs, indicating a lack of discriminative power. The best multi-mRNA diagnostic classifier showed moderate discriminative power [AUC = 0.81] for paediatric inactive IBD, but was not able to discriminate active or inactive adult IBD patients from controls. The AUC-ROC values did not confirm an ability of the mRNAs abundances to discriminate between active ulcerative colitis and active Crohn's disease in paediatric or adult populations.
This study identifies and validates blood transcriptional biomarkers that could be used in clinical settings as diagnostic predictors of IBD clinical activity in paediatric, but not adult, IBD patients.
本研究旨在探讨全血基因表达谱在诊断炎症性肠病(IBD)中的实际应用价值。
发现队列包括 102 例和 51 例儿科 IBD 患者和对照者,以及 95 例和 46 例成人 IBD 患者和对照者;验证队列包括 447 例和 76 例儿科 IBD 患者和对照者,以及 271 例和 108 例成人 IBD 患者和对照者。在发现阶段,使用 RNA-Seq 分析从全外周血中提取的 RNA 样本,并使用定量聚合酶链反应(qPCR)验证选定生物标志物的预测值。
总共从发现测序数据集中选择了 15 个差异表达的转录本[调整后的 p 值≤0.05]。在验证分析中,接受者操作特征曲线和曲线下面积(ROC-AUC)显示,在患有活动性 IBD 的儿科患者中,11 个 mRNA 的区分能力较高(AUC 范围为 0.91-0.98)。相比之下,在比较非活动性儿科 IBD 与活动性/非活动性成人 IBD 时,AUC-ROC 值范围为 0.63-0.75,表明区分能力不足。最佳的多-mRNA 诊断分类器对儿科非活动性 IBD 具有中等的区分能力[AUC=0.81],但无法区分成人活动性或非活动性 IBD 患者与对照者。AUC-ROC 值并不能确认这些 mRNA 丰度在儿科或成人人群中区分活动性溃疡性结肠炎和活动性克罗恩病的能力。
本研究鉴定并验证了血液转录生物标志物,这些标志物可在临床环境中作为儿科 IBD 患者临床活动的诊断预测因子使用,但不能用于成年 IBD 患者。